- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
London Today
By the People, for the People
Ozempic-Style Drugs May Reduce Heart Attack Complications
New research suggests GLP-1 medications could prevent life-threatening 'no-reflow' condition
Published on Mar. 5, 2026
Got story updates? Submit your updates here. ›
According to a study published in Nature Communications, a class of weight-loss drugs that mimic the hormone GLP-1 may help prevent a dangerous complication called 'no-reflow' in nearly half of heart attack patients. The research found that GLP-1 drugs trigger a brain-gut-heart signaling pathway that opens up tiny blood vessels in the heart, improving blood flow and reducing the risk of heart failure and death.
Why it matters
Heart attacks often leave microscopic blood vessels in the heart muscle narrowed or blocked, a condition known as 'no-reflow' that increases the risk of heart failure and death. If GLP-1 drugs can reliably prevent this complication, it could significantly improve outcomes for heart attack patients.
The details
The study, led by researchers at the University of Bristol and University College London, used animal models and cellular imaging to track how GLP-1 interacts with heart tissue. They found that when GLP-1 is released or administered as a drug, it sends a signal from the gut to the brain, which then triggers the opening of potassium channels in specialized cells called pericytes. This allows the small blood vessels (capillaries) to widen and improve blood flow to the heart muscle. When the researchers removed the potassium channels, the drugs no longer provided this protective effect.
- The study was published on March 5, 2026.
The players
Dr. Svetlana Mastitskaya
The lead author of the study and a senior lecturer at Bristol Medical School.
University of Bristol
The institution where the lead researcher is based and where the study was conducted.
University College London
The institution that collaborated with the University of Bristol on the research.
British Heart Foundation
The organization that primarily funded the research.
GLP-1 drugs
A class of weight-loss medications that mimic the hormone glucagon-like peptide-1, which helps regulate blood sugar and appetite.
What they’re saying
“In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment. This results in a complication known as 'no-reflow,' where blood is unable to reach certain parts of the heart tissue.”
— Dr. Svetlana Mastitskaya, Lead author of the study and senior lecturer at Bristol Medical School (Press release)
What’s next
Clinical trials are necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans. Additionally, the study does not establish whether long-term use of GLP-1 medications provides a pre-existing level of protection against heart attack complications.
The takeaway
This research suggests that existing GLP-1 drugs used for type 2 diabetes and obesity could potentially be repurposed as emergency treatments during or immediately after a heart attack to reduce tissue damage and improve outcomes for patients. If confirmed in human trials, this could be a significant advancement in the treatment of heart attack complications.
